Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosures
3. Acknowledgements
4. Lecture structure
5. Why neuroimaging in AD?
6. Improving clinical diagnosis and prediction of AD
7. Assessing disease modification
8. Structural imaging to diagnose AD
9. Cerebral perfusion and metabolism
10. Tissue microstructure
11. Metabolites and microbleeds
12. Molecular imaging
13. Imaging of mice and (wo)men
14. Challenges for research biomarkers
15. Measuring progression and drug discovery
16. Challenges for clinical practice
17. European and US guidelines on diagnosis
18. Moving beyond excluding tumours
19. Reality of clinical practice
20. Atrophy: an inevitable consequence
21. Increased space between the gyri
22. Hippocampus reduced by 20% in early AD
23. Atrophy on MRI: AD vs. aging and dementia
24. Visual assessment of atrophy on MRI (1)
25. Visual assessment of atrophy on MRI (2)
26. Functional imaging FDG-PET: metabolic patterns
27. Imaging as a biomarker for early AD diagnosis
28. New diagnostic criteria for AD
29. Supportive features
30. Trials: imaging to help define study population
31. Hippocampal atrophy
32. Medial temporal lobe atrophy
33. Neurodegeneration and structural readjustments
34. CSF spaces are growing due to AD
35. Gyri contract and spaces expand in AD
36. Atrophy acceleration in AD
37. Progression from MCI to AD
38. Diagnosis on post mortem AD: Braak stage VI
39. Amyloid imaging in AD patients and control
40. Imaging biomarkers as outcome measures
41. Increasing efficiency and interpretability of trials
42. Imaging markers of disease-modification
43. Imaging - disease modification markers
44. Serial coronal MRI of a patient - initially mild AD
45. AD: brain volume vs. time (1)
46. Registration
47. Register scans of an AD patient
48. Rate of brain atrophy in early-onset AD
49. Mild cognitive impairment stage scan (1)
50. Mild cognitive impairment stage scan (2)
51. Insight into earliest changes?
52. MRI changes in familial AD
53. Serial MRI scan of brain changes in AD
54. Brain volume as percentage of TIV
55. AD: brain volume vs. time (2)
56. Rates of atrophy in AD from serial MRI
57. Power analyses from ADNI
58. ADNI power analysis for MRI: atrophy
59. A cascade of spreading pathological change?
60. ADNI - 1 year BSI data
61. Imaging measures to assess negative drug effects
62. Serial MRI allows recognition of new lesions
63. Problems and concerns
64. Whole brain loss (BSI) in immunotherapy
65. PIB retention stable over 2 years
66. Disease modification: differing views
67. Combine imaging markers
68. Imaging biomarkers
69. Images of progression
70. Concluding remarks

Topics Covered

• Imaging in Alzheimer's Disease (AD) trials
• Increasing range of modalities to measure brain structure, function and molecular pathology of AD
• Early diagnosis, inclusion markers and measurement of progression
• MRI to measure atrophy
• PET to measure amyloid

Links

Series:

• Alzheimer's Disease

Categories:

• Clinical Practice
• Methods
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on August 26, 2010

Financial Disclosures

• Prof. Nick Fox has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.